Espansione Group Recognized in TFOS DEWS III Report
The TFOS (Tear Film and Ocular Surface Society) DEWS III Report, published in the American Journal of Ophthalmology, has acknowledged LM™ LLLT photobiomodulation and the eye-light® platform as clinical tools for the management of tear film instability and Dry Eye Disease — marking the first time Espansione's technology has been included in this landmark consensus document.
What Is the TFOS DEWS III?
TFOS DEWS III is the world's most comprehensive consensus report on dry eye disease, covering definition, diagnosis, and management. It provides an evidence-based framework for eyecare practitioners globally. This latest edition is an eight-year update to the previous DEWS report.
What Was Acknowledged
The report cites multiple peer-reviewed, randomised and controlled trials demonstrating significant improvements in:
- Tear film stability
- Meibomian gland function
- Patient-reported symptoms
...following LM™ LLLT treatment on the eye-light® platform, alongside OPE™ IPL.
On blue LM™ LLLT specifically, the report notes its potential to reduce bacterial biofilm on lid margins via antimicrobial properties — supporting faster resolution of blepharitis.
Significance
Matteo Corbellino, Chief Marketing & Innovation Officer at Espansione Group, commented:
"The inclusion of our proprietary therapeutic technologies in the TFOS DEWS III report, the gold standard for dry eye and ocular surface management, is an important recognition of the growing awareness and momentum our solutions have been gaining."
About the eye-light® Device
eye-light® is CE marked as a Class IIA medical device. It integrates LM™ LLLT (Red, Blue, Yellow) and OPE™ IPL in a single modular platform, designed for ophthalmic clinical workflows. Since February 2025, Espansione Group operates as part of EssilorLuxottica.